Cargando…

COVID-19 vaccine capacity: Challenges and mitigation – The DCVMN perspective

Vaccine manufacturers from developing countries have a proven track record of developing, producing, and supplying high-quality vaccines globally. However, due to the complexity of vaccine manufacturing, numerous stakeholder organizations support manufacturers across a variety of functions. To optim...

Descripción completa

Detalles Bibliográficos
Autores principales: Hayman, Benoit, Suri, Rajinder, Prasad, Sai D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8275514/
https://www.ncbi.nlm.nih.gov/pubmed/34325932
http://dx.doi.org/10.1016/j.vaccine.2021.07.007
_version_ 1783721731334078464
author Hayman, Benoit
Suri, Rajinder
Prasad, Sai D.
author_facet Hayman, Benoit
Suri, Rajinder
Prasad, Sai D.
author_sort Hayman, Benoit
collection PubMed
description Vaccine manufacturers from developing countries have a proven track record of developing, producing, and supplying high-quality vaccines globally. However, due to the complexity of vaccine manufacturing, numerous stakeholder organizations support manufacturers across a variety of functions. To optimize the support from stakeholders it is instrumental to first understand which manufacturing processes these manufacturers require support for and what support functions are most beneficial. To this end, the Developing Countries Vaccine Manufacturers Network designed a comprehensive survey to assess the specific needs of the Network’s member organizations. We found that almost all sampled manufacturers are interested in obtaining funding or technology transfers for COVID-19 vaccines. Furthermore, results indicated that manufacturers have a strong appetite for modern technology platforms, particularly RNA technologies. Scale-up, phase III clinical trials, and formulation were also key processes for which manufacturers require support.
format Online
Article
Text
id pubmed-8275514
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-82755142021-07-14 COVID-19 vaccine capacity: Challenges and mitigation – The DCVMN perspective Hayman, Benoit Suri, Rajinder Prasad, Sai D. Vaccine Short Communication Vaccine manufacturers from developing countries have a proven track record of developing, producing, and supplying high-quality vaccines globally. However, due to the complexity of vaccine manufacturing, numerous stakeholder organizations support manufacturers across a variety of functions. To optimize the support from stakeholders it is instrumental to first understand which manufacturing processes these manufacturers require support for and what support functions are most beneficial. To this end, the Developing Countries Vaccine Manufacturers Network designed a comprehensive survey to assess the specific needs of the Network’s member organizations. We found that almost all sampled manufacturers are interested in obtaining funding or technology transfers for COVID-19 vaccines. Furthermore, results indicated that manufacturers have a strong appetite for modern technology platforms, particularly RNA technologies. Scale-up, phase III clinical trials, and formulation were also key processes for which manufacturers require support. Elsevier Ltd. 2021-08-16 2021-07-13 /pmc/articles/PMC8275514/ /pubmed/34325932 http://dx.doi.org/10.1016/j.vaccine.2021.07.007 Text en © 2021 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Short Communication
Hayman, Benoit
Suri, Rajinder
Prasad, Sai D.
COVID-19 vaccine capacity: Challenges and mitigation – The DCVMN perspective
title COVID-19 vaccine capacity: Challenges and mitigation – The DCVMN perspective
title_full COVID-19 vaccine capacity: Challenges and mitigation – The DCVMN perspective
title_fullStr COVID-19 vaccine capacity: Challenges and mitigation – The DCVMN perspective
title_full_unstemmed COVID-19 vaccine capacity: Challenges and mitigation – The DCVMN perspective
title_short COVID-19 vaccine capacity: Challenges and mitigation – The DCVMN perspective
title_sort covid-19 vaccine capacity: challenges and mitigation – the dcvmn perspective
topic Short Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8275514/
https://www.ncbi.nlm.nih.gov/pubmed/34325932
http://dx.doi.org/10.1016/j.vaccine.2021.07.007
work_keys_str_mv AT haymanbenoit covid19vaccinecapacitychallengesandmitigationthedcvmnperspective
AT surirajinder covid19vaccinecapacitychallengesandmitigationthedcvmnperspective
AT prasadsaid covid19vaccinecapacitychallengesandmitigationthedcvmnperspective